Verastem (VSTM) “announced encouraging preliminary data from the first two dose levels in its ongoing Phase 1/2a clinical trial evaluating ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Ventyx Biosciences, Inc. surged after strong Phase 2 results for VTX3232 in obesity. Click for key insights and what VTYX ...
Zymeworks (ZYME) announced preliminary results from a Phase 1 study evaluating ZW191, an antibody-drug conjugate targeting folate receptor-alpha, ...
First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...
The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...
IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / / Medicus Pharma Ltd.
Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback